香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 承董事會命 趙大君 主 席 於本公告刊發日期，董事會包括以下人士： 海外監管公告 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司 2025 年半年度募集資金存放與實際使用情況專項報告的公告》，僅供參閱。該文件及 其披露內容乃根據中國法律法規及境內相關監管要求而編制及刊發。 中國·上海 二零二五年八月十二日 *僅供識別 趙大君先生（執行董事） 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先生（獨立非執行董事） 林兆榮先生（獨立非執行董事） 徐培龍先生（獨立非執行董事） 股票代码：688505 股票简称：复旦张江 编号：临2025-027 上海复旦张江生物医药股份有限公司 2025 年半年度募集资金存放与实际使用情况专项报告的 ...

报告期内利润总额等相关财务指标下降明显，主要因为研发费用较上年同期有所增长，以及上年同期与 里葆多推广服务商上海辉正终止合作后，公司确认相应补偿款及违约金。 人民财讯8月12日电，复旦张江(688505)8月12日晚间发布2025年半年报，上半年营业收入3.9亿元，同比 下降4.42%；归母净利润571.51万元，同比下降91.89%。 ...

[Definitions](index=5&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) This section defines professional, financial, and industry-specific terms crucial for report comprehension - The report provides definitions for professional terminology, company entity abbreviations, financial terms, and industry-specific vocabulary such as photodynamic, ADC, and liposome, to aid in understanding the report's content[13](index=13&type=chunk)[14](index=14&type=chunk) [Company Profile and Key Financial Indicators](index=7&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) [Company Overview](index=7&type=section&id=%E4%B8%80%E3%80%81%20%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) Basic company information, including names, legal representative, addresses, and contact details, is provided Basic Company Information | Item | Information | | :--- | :--- | | **Chinese Name** | 上海复旦张江生物医药股份有限公司 | | **A-share Abbreviation** | 复旦张江 (688505) | | **H-share Abbreviation** | 复旦张江 (01349) | | **Legal Representative** | 赵大君 | | **Registered Address** | 上海市浦东新区张江高科技园区蔡伦路308号 | [Key Accounting Data and Financial Indicators](index=8&type=section&id=%E5%85%AD%E3%80%81%20%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) Revenue decreased **4.42%**, net profit attributable to parent company shareholders plummeted **91.89%**, and operating cash flow rose **125%** Key Accounting Data (RMB Yuan) | Key Accounting Data | Current Period (Jan-Jun) | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 390,083,112 | 408,123,863 | -4.42 | | Net Profit Attributable to Shareholders of Listed Company | 5,715,142 | 70,473,064 | -91.89 | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Items) | -9,491,857 | 43,678,080 | -121.73 | | Net Cash Flow from Operating Activities | 62,212,859 | 27,649,549 | 125.00 | Key Financial Indicators | Key Financial Indicators | Current Period (Jan-Jun) | Prior Year Period | Change | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (RMB Yuan/share) | 0.01 | 0.07 | -85.71% | | Weighted Average Return on Net Assets (%) | 0.25 | 2.99 | Decrease by 2.74 percentage points | | R&D Investment as % of Operating Revenue (%) | 45.63 | 38.06 | Increase by 7.57 percentage points | - The significant decline in profit-related indicators is attributed to increased R&D expenses in the current period compared to the prior year and a high comparative base in the prior year due to one-time compensation and liquidated damages from the termination of cooperation with Libaoduo®'s promotion service provider, Shanghai Huizheng[22](index=22&type=chunk) [Management Discussion and Analysis](index=10&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) [Industry and Principal Business Operations](index=10&type=section&id=%E4%B8%80%E3%80%81%20%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E5%8F%8A%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) The company's core business is innovative biopharmaceutical R&D, production, and marketing, with products in dermatology and oncology - National policies, including "Deepening Medical and Health System Reform 2024 Key Tasks" and "Implementation Plan for Full-Chain Support of Innovative Drug Development," continue to favor the innovative drug industry[30](index=30&type=chunk)[31](index=31&type=chunk) - The company's principal business revenue is derived from three core products: - **Dermatology products**: Aminolevulinic acid topical powder (Aila®), the world's first photodynamic drug for condyloma acuminatum; Haemoporfin for injection (Fumeida®), the world's first photodynamic drug for port-wine stains - **Oncology products**: Long-circulating doxorubicin hydrochloride liposome injection (Libaoduo®), the first domestic generic nano-drug[39](index=39&type=chunk)[43](index=43&type=chunk)[46](index=46&type=chunk) [Discussion and Analysis of Operations](index=15&type=section&id=%E4%BA%8C%E3%80%81%20%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E7%9A%84%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) Strategic focus on photodynamic and ADC drugs continues, but Libaoduo®'s price reduction will negatively impact future sales - **Photodynamic drug pipeline progress**: - **Aminolevulinic acid**: Phase II clinical trials for cervical intraepithelial neoplasia (CIN) and moderate-to-severe acne are complete, with Phase III to commence soon; Phase II for actinic keratosis (AK) enrollment is complete; validation clinical for intraoperative visualization of glioblastoma enrollment is complete, with marketing application to be submitted soon; validation clinical for bladder cancer surgical resection assistance has completed first patient enrollment - **FZ-P001 sodium**: Phase I clinical trial application for intraoperative visualization of malignant lesions in cancer has been accepted[55](index=55&type=chunk)[56](index=56&type=chunk)[57](index=57&type=chunk)[58](index=58&type=chunk)[59](index=59&type=chunk) - **Antibody-drug conjugate (ADC) pipeline progress**: - **Anti-Trop2-SN38 (FDA018)**: Phase III clinical study for triple-negative breast cancer is ongoing - **Anti-Her2-BB05 (FDA022)**: Phase II clinical enrollment for HER2-low expression breast cancer is complete, with preliminary data obtained - **Anti-Trop2-BB05 (FZ-AD004)**: Phase I clinical study is underway - **Anti-DLL3-BB05 (FZ-AD005)**: Phase I clinical study is underway, with smooth clinical progress[62](index=62&type=chunk) - The anti-tumor drug Libaoduo®'s market retail price will decrease by no less than **35%** from May 1, 2025, due to its non-selection in national centralized procurement, negatively impacting 2025 and subsequent annual sales revenue[64](index=64&type=chunk) [Analysis of Core Competencies](index=19&type=section&id=%E4%B8%89%E3%80%81%20%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) Core competitiveness is driven by four technology platforms and strategic focus on photodynamic and ADC drugs, with increased R&D investment - The company has established four core technology platforms—gene engineering, photodynamic, nanotechnology, and oral solid dosage forms—with a strategic focus on photodynamic and antibody-drug conjugate (ADC) drugs, forming a competitive R&D profile[73](index=73&type=chunk)[74](index=74&type=chunk)[75](index=75&type=chunk)[76](index=76&type=chunk) R&D Investment (RMB Yuan) | Item | Current Period Amount | Prior Year Period Amount | Change (%) | | :--- | :--- | :--- | :--- | | Expensed R&D Investment | 177,976,257 | 154,592,537 | 15.13 | | Capitalized R&D Investment | - | 737,612 | -100.00 | | **Total R&D Investment** | **177,976,257** | **155,330,149** | **14.58** | | R&D Investment as % of Operating Revenue | 45.63% | 38.06% | Increase by 7.57 percentage points | - During the reporting period, the company filed **7** new patent applications, obtained **14** patents (including **12** invention patents), and cumulatively holds **63** valid invention patents[80](index=80&type=chunk) [Risk Factors](index=28&type=section&id=%E5%9B%9B%E3%80%81%20%E9%A3%8E%E9%99%A9%E5%9B%A0%E7%B4%A0) Risks include R&D failure, talent loss, lack of a controlling shareholder, product concentration, and drug price reductions - The company's main products, Aila®, Libaoduo®, and Fumeida®, account for a significant portion of revenue, posing a risk of product concentration[94](index=94&type=chunk) - Libaoduo®'s non-selection in the tenth round of national centralized procurement led to a price reduction of no less than **35%**, with projected 2025 sales revenue decreasing by over **50%** and potential single-product losses[96](index=96&type=chunk) - The absence of a controlling shareholder and actual controller may lead to an unstable corporate governance structure or reduced decision-making efficiency[93](index=93&type=chunk) [Analysis of Key Operating Performance](index=30&type=section&id=%E4%BA%94%E3%80%81%20%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E4%B8%BB%E8%A6%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5) Core product sales showed mixed performance, with Aila® growing, while Libaoduo® and Fumeida® declined, leading to a **4.42%** revenue decrease - Core product sales revenue year-on-year changes: - **Aila®**: Increased by **2%** - **Libaoduo®**: Decreased by **16%** - **Fumeida®**: Decreased by **7%**[98](index=98&type=chunk)[99](index=99&type=chunk) Financial Statement Key Item Variation Analysis (RMB Yuan) | Item | Current Period Amount | Prior Year Period Amount | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 390,083,112 | 408,123,863 | -4.42 | | Operating Cost | 39,773,796 | 29,399,848 | 35.29 | | Selling Expenses | 181,910,272 | 114,492,701 | 58.88 | | R&D Expenses | 177,976,257 | 154,592,537 | 15.13 | | Net Cash Flow from Operating Activities | 62,212,859 | 27,649,549 | 125.00 | - The company's Taizhou production base's antibody-drug conjugate (ADC) workshop is now capable of commercial-scale production, supporting Phase III clinical trials and future commercialization of ADC projects[100](index=100&type=chunk) [Corporate Governance, Environment, and Society](index=37&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) [Corporate Governance, Environment, and Society](index=37&type=section&id=%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) No changes in key personnel or profit distribution plans, with social responsibility efforts including purchasing agricultural products - No changes occurred in the company's directors, supervisors, senior management, or core technical personnel during the reporting period[119](index=119&type=chunk) - The company does not plan any profit distribution or capital reserve conversion to share capital for the half-year period[119](index=119&type=chunk) - The company actively fulfilled its social responsibilities by purchasing **RMB 61,425** worth of agricultural products from impoverished mountainous areas to support rural revitalization[120](index=120&type=chunk) [Significant Matters](index=38&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) [Fulfillment of Commitments](index=38&type=section&id=%E4%B8%80%E3%80%81%20%E6%89%BF%E8%AF%BA%E4%BA%8B%E9%A1%B9%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) All relevant parties, including major shareholders, directors, and senior management, strictly fulfilled their IPO commitments - The company's actual controller, shareholders, related parties, and the company itself strictly fulfilled all commitments made during or continuing into the reporting period[122](index=122&type=chunk) [Progress of Raised Funds Utilization](index=48&type=section&id=%E5%8D%81%E4%BA%8C%E3%80%81%20%E5%8B%9F%E9%9B%86%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E8%BF%9B%E5%B1%95%E8%AF%B4%E6%98%8E) The company utilized **RMB 841 million** of its **RMB 974 million** net proceeds, with over-raised funds fully allocated to working capital, and the "Haemoporfin US Registration Project" delayed Overall Utilization of Raised Funds (10,000 RMB Yuan) | Item | Amount | | :--- | :--- | | Net Proceeds | 97,432.39 | | Total Committed Investment | 65,000 | | Total Over-raised Funds | 32,432.39 | | Total Cumulative Investment as of Reporting Period End | 84,075.19 | | Cumulative Investment Progress | 86.29% | - The "Haemoporfin US Registration Project" has been delayed by **two years** to December 31, 2025, due to external factors affecting its progress[138](index=138&type=chunk) - The company uses temporarily idle raised funds, up to **RMB 180 million**, for cash management by purchasing principal-protected wealth management products or deposit-type products to enhance fund utilization efficiency[142](index=142&type=chunk) [Share Changes and Shareholder Information](index=53&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) [Shareholder Information](index=53&type=section&id=%E4%BA%8C%E3%80%81%20%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) The company had **19,877** common shareholders, with HKSCC NOMINEES LIMITED and Shanghai Pharmaceuticals Holding Co., Ltd. as the top two, indicating a dispersed ownership structure - As of the end of the reporting period, the company had a total of **19,877** common shareholders, comprising **19,737** A-share holders and **140** H-share holders[148](index=148&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Number of Shares Held (shares) | Shareholding Ratio (%) | Share Type | | :--- | :--- | :--- | :--- | | HKSCC NOMINEES LIMITED | 257,748,240 | 24.85 | H-share | | Shanghai Pharmaceuticals Holding Co., Ltd. | 210,142,560 | 20.27 | A-share + H-share | | Xinqi Phase II Venture Capital Enterprise | 156,892,912 | 15.14 | A-share | | Yang Zongmeng | 75,743,494 | 7.31 | H-share | | Wang Haibo | 56,099,327 | 5.41 | A-share | [Bond-Related Information](index=58&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) [Bond-Related Information](index=58&type=section&id=%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) The company had no outstanding corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible corporate bonds - The company had no corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible corporate bonds during the reporting period[156](index=156&type=chunk) [Financial Report](index=59&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) [Consolidated Balance Sheet](index=61&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of June 30, 2025, total assets were **RMB 2.54 billion** (down **1.74%**), net assets attributable to shareholders **RMB 2.28 billion** (down **1.07%**), with **RMB 1.11 billion** in cash Consolidated Balance Sheet Key Items (RMB Yuan) | Item | June 30, 2025 | December 31, 2024 | Change (%) | | :--- | :--- | :--- | :--- | | **Total Assets** | **2,541,453,272** | **2,586,502,623** | **-1.74** | | Total Current Assets | 1,593,438,095 | 1,606,778,507 | -0.83 | | Total Non-current Assets | 948,015,177 | 979,724,116 | -3.24 | | **Total Liabilities** | **261,015,209** | **281,225,518** | **-7.19** | | **Total Equity Attributable to Parent Company Shareholders** | **2,279,821,312** | **2,304,567,412** | **-1.07** | [Consolidated Income Statement](index=65&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) In H1 2025, operating revenue was **RMB 390 million** (down **4.42%**), operating profit **RMB 5.73 million**, and net profit attributable to parent company shareholders **RMB 5.72 million** (down **91.89%**), due to increased R&D and selling expenses Consolidated Income Statement Key Items (RMB Yuan) | Item | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 390,083,112 | 408,123,863 | -4.42 | | Operating Cost | (39,773,796) | (29,399,848) | 35.29 | | Selling Expenses | (181,910,272) | (114,492,701) | 58.88 | | R&D Expenses | (177,976,257) | (154,592,537) | 15.13 | | Operating Profit | 5,726,060 | 72,223,824 | -92.07 | | **Net Profit Attributable to Parent Company Shareholders** | **5,715,142** | **70,473,064** | **-91.89** | [Consolidated Cash Flow Statement](index=68&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Net cash flow from operating activities increased by **125.00%** to **RMB 62.21 million** due to increased sales, with investing activities showing a net outflow of **RMB 8.28 million**, and cash equivalents totaling **RMB 1.11 billion** Consolidated Cash Flow Statement Key Items (RMB Yuan) | Item | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 62,212,859 | 27,649,549 | 125.00 | | Net Cash Flow from Investing Activities | (8,277,485) | 4,326,668 | -291.31 | | Net Cash Flow from Financing Activities | (3,638,269) | (5,522,836) | N/A | | **Net Increase in Cash and Cash Equivalents** | **50,205,176** | **26,585,009** | **88.85** |

Core Viewpoint - Fudan Zhangjiang reported a significant decline in both revenue and net profit for the first half of the year, primarily due to increased R&D expenses and the absence of compensation from a previous partnership [1] Financial Performance - The company achieved a revenue of 390 million yuan, representing a year-on-year decrease of 4.42% [1] - The net profit attributable to shareholders was 5.71 million yuan, down 91.89% from 70.47 million yuan in the same period last year [1] - Basic earnings per share were reported at 0.01 yuan [1] Factors Influencing Performance - The decline in financial metrics was mainly attributed to an increase in R&D expenses compared to the previous year [1] - The previous year's financials included compensation and penalties from the termination of a partnership with Shanghai Huizheng, which did not recur in the current reporting period [1]

复旦张江公告，2025年上半年营业收入3.9亿元，同比下降4.42%。净利润571.51万元，同比下降 91.89%。 ...

海外監管公告 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司 2025 年度"提質增效重回報"行動方案的半年度評估報告》，僅供參閱。該文件及其 披露內容乃根據中國法律法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 於本公告刊發日期，董事會包括以下人士： 中國·上海 二零二五年八月十二日 *僅供識別 趙大君先生（執行董事） 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先生（獨立非執行董事） 林兆榮先生（獨立非執行董事） 徐培龍先生（獨立非執行董事） 上海复旦张江生物医药股份有限公司 2025 年度"提质增效重回报"行动方案的半年度评估报告 为践行"以投资者为本"的上市公司发展理念，维护上海复旦张江生物医药股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司第 八屆監事會第十次會議決議公告》，僅供參閱。該文件及其披露內容乃根據中國法律 法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 於本公告刊發日期，董事會包括以下人士： 中國·上海 第八届监事会第十次会议决议公告 二零二五年八月十二日 *僅供識別 趙大君先生（執行董事） 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先生（獨立非執行董事） 林兆榮先生（獨立非執行董事） 徐培龍先生（獨立非執行董事） 股票代码：688505 股票简称：复旦张江 编号：临2025-026 上海复旦张江生物医药股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假 ...

Core Viewpoint - The article discusses the performance of the Shanghai Composite Index and the Hang Seng Index, along with the premium of Fudan Zhangjiang's A-shares over H-shares, highlighting the company's position in the biopharmaceutical industry and its ongoing innovations in drug development [1][2]. Group 1: Market Performance - On August 12, the Shanghai Composite Index rose by 0.5%, closing at 3665.92 points, while the Hang Seng Index increased by 0.25%, closing at 24969.68 points [1]. - Fudan Zhangjiang's A-share premium reached 187.84%, ranking third among A/H shares [1]. Group 2: Company Overview - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1]. - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [1]. - Fudan Zhangjiang has developed competitive advantages in various fields, including gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new drugs expected to be launched in the market [1]. - The company has undertaken several national key technology projects and major scientific initiatives, demonstrating its strength in the biopharmaceutical field [1].

天眼查商业履历信息显示，上海复旦张江生物医药股份有限公司，成立于1996年，位于上海市，是一家 以从事专业技术服务业为主的企业。企业注册资本10365.721万人民币，实缴资本10365.721万人民币。 公司法定代表人为赵大君。 通过天眼查大数据分析，上海复旦张江生物医药股份有限公司共对外投资了8家企业，参与招投标项目 270次，知识产权方面有商标信息44条，专利信息184条，此外企业还拥有行政许可78个。 来源：金融界 金融界消息 截至2025年8月8日收盘，复旦张江（688505）报收于10.36元，下跌0.96%，换手率1.5%， 成交量10.62万手，成交金额1.11亿元。 资金流向方面，今日主力资金净流出1771.07万元，占比成交额15.99%。其中，超大单净流出411.12万 元、占成交额3.71%，大单净流出1359.95万元、占成交额12.28%，中单净流出流入1055.91万元、占成 交额9.54%，小单净流入715.17万元、占成交额6.46%。 复旦张江最新一期业绩显示，截至2025一季报，公司营业总收入1.80亿元、同比增长21.85%，归属净利 润266.51万元，同比增长13. ...

上海复旦张江生物医药股份有限公司（股票代码：688505.SH）财务总监薛燕以140.46万元年薪位列上海地区医药生物行业CFO薪酬榜第8名。 其薪酬虽较2023年的151.70万元下降7.41%（减少11.24万元），但仍显著高于A股CFO平均年薪81.48万元，并跻身区域行业前十。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平 这一排名凸显上海医药生物（申万一级）行业对顶尖财务人才的高溢价效应：该行业395家上市公司CFO平均年薪91.97万元，而上海39家企业CFO平均年薪达113.91万元，较全市场均值高出3 薛燕的职业履历成为其薪酬竞争力的关键支撑。这位1981年出生的财务高管现任复旦张江执行董事、副总经理、财务总监及董事会秘书，同时兼任风屹（香港）控股董事及上海汉都医药监事。 她拥有香港大学工商管理硕士学位（2018年）和上海财经大学国际会计学士学位（2004年）， ...